公开(公告)号：EP4285938A1

公开(公告)日：2023-12-06

申请号：EP22746295.9

申请日：2022-01-28

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  CHOI, Sea Rom ,  HWANG, Chae Young ,  LEE, Jong Hoon

IPC: A61K48/00 ,  A61K31/7105 ,  A61K38/15 ,  A61K31/138 ,  A61K45/06 ,  A61P35/00 ,  A23L33/13 ,  A23L33/18

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing malignant breast cancer and, more particularly, to a composition for transdifferentiation of ER-negative breast cancer to luminal breast cancer, comprising an HDAC1/2 inhibitor and a BCL11A inhibitor as active ingredients, and use of the composition. According to the present invention, when target genes of the present invention are inhibited, BLT is induced so that basal-like or triplet-negative breast cancer is transdifferentiated to luminal A subtype breast cancer which is responsive to anticancer therapy, that is, being curable by hormone therapy. Accordingly, an effective and novel drug treatment that has not been conventionally attempted may be provided, thereby not only increasing the survival rate of patients through targeted therapy by realizing personalized medicine, but also contributing to an improvement in the quality of life that results from unnecessary anticancer drug therapy.